Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months of therapy. RESULTS: In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (hazard ratio with dabigatran, 1.44; 95% confidence interval [CI], 0.78 to 2.64; P=0.01 for noninferiority). Major bleeding occurred in 13 patients in the dabigatran group (0.9%) and 25 patients in the warfarin group (1.8%) (hazard ratio, 0.52; 95% CI, 0.27 to 1.02). Major or clinically relevant bleeding was less frequent with dabigatran (hazard ratio, 0.54; 95% CI, 0.41 to 0.71). Acute coronary syndromes occurred in 13 patients in the dabigatran group (0.9%) and 3 patients in the warfarin group (0.2%) (P=0.02). In the placebo-control study, recurrent venous thromboembolism occurred in 3 of 681 patients in the dabigatran group (0.4%) and 37 of 662 patients in the placebo group (5.6%) (hazard ratio, 0.08; 95% CI, 0.02 to 0.25; P<0.001). Major bleeding occurred in 2 patients in the dabigatran group (0.3%) and 0 patients in the placebo group. Major or clinically relevant bleeding occurred in 36 patients in the dabigatran group (5.3%) and 12 patients in the placebo group (1.8%) (hazard ratio, 2.92; 95% CI, 1.52 to 5.60). Acute coronary syndromes occurred in 1 patient each in the dabigatran and placebo groups. CONCLUSIONS: Dabigatran was effective in the extended treatment of venous thromboembolism and carried a lower risk of major or clinically relevant bleeding than warfarin but a higher risk than placebo. (Funded by Boehringer Ingelheim; RE-MEDY and RE-SONATE ClinicalTrials.gov numbers, NCT00329238 and NCT00558259, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For patients who are treated with dabigatran for secondary prevention, only the standard regimen of 150 mg twice daily has been studied. 310”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Self-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Self-citation(2003) · New England Journal of Medicine · doi:10.1056/nejmoa035451 · Cited by 887
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Self-citationKearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationNewly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Research works printed but not linked: 1
- 8. Cochrane Database Syst Rev 2000;3: CD001367.
Cited by
Items 901–1,000 of 1,000
EXTENDED ANTICOAGULANT THERAPYIN PATIENTS, WHO SURVIVED PULMONARY EMBOLISM
Vorobieva, N. M., & Панченко, Е. П. (2018) · Aterotromboz = Atherothrombosis · doi:10.21518/2307-1109-2018-2-36-45
Pierpaolo, D. M. (2018) · Journal of Clinical Case Reports · doi:10.4172/2165-7920.10001188
Валерьевич, А. О., Vechorko, V. I., & Shapsigova, O. A. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-21-8-15
Pharmacological Treatment of Venous Disorders
Kalodiki, E., & Fareed, J. (2014) · Springer eBooks · doi:10.1007/978-3-642-37393-0_223-1
A vénás tromboembólia kezelése ma, 10 évvel az első direkt orális antikoaguláns megjelenése után
Vértes, A. (2019) · Cardiologia Hungarica · doi:10.26430/chungarica.2019.49.1.51
Zafarová, Z. (2014) · Cor et Vasa · doi:10.33678/cor.2014.052
Kano), 狩. 謙. (., 訓生, 濱., 博之, 田., 賢, 別., 望, 笹., 伸朗, 志., & 慶, 西. (2017) · Nihon Kyukyu Igakukai Zasshi Journal of Japanese Association for Acute Medicine · doi:10.1002/jja2.12224
Efficacy and safety of direct oral anticoagulants in patients with pulmonary thromboembolism
Zlobina, D. S., & Koroleva, L. Y. (2019) · Medical Almanac · doi:10.21145/2499-9954-2019-2-51-54
“С целью изучения возможности использования дабигатрана для длительной антикоагулянтной терапии были организованы два рандомизированных двойных слепых исследования: RE-MEDY (сравнение дабигатрана с варфарином) и RE-SONATE (сравнение дабигатрана с плацебо) [20].”
Venous Disorders: Medical Management
Kalodiki, E., & Fareed, J. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_223
Gondolatok a direkt orális véralvadásgátló szerek használatáról krónikus vesebetegségben
Ábrahám, G. (2018) · Diabetologia Hungarica · doi:10.24121/dh.2018.17
A Review of the Medical Challenges of Using Direct Oral Anticoagulants in Real-World Practice
-, I. C. (2019) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-019-00001-9
Routine Anticoagulation for the Provoked and Unprovoked VTE
Bosch, M. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-25782-8_2
von Diersburg, V. T. F. R. (2020) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7872
Storck, M., Huppert, P., Amendt, K., & Grundmann, R. T. (2020) · Gefässchirurgie · doi:10.1007/s00772-020-00630-7
Barillari, G., Bortoluzzi, C., Giorgi, M., Orabona, R., Pacetti, E., Sciatti, E., Zaffaroni, M., & Dentali, F. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02300-8
Instituto de Investigaciones Clínicas “Dr. Américo Negrette”, F. D. M., Vizcaíno, G., Instituto de Investigación. Universidad Técnica Manabí, P. E., Medina, J. W., Instituto Hematológico de Occidente, M., Quintero, J., Instituto de Investigaciones Clínicas “Dr. Américo Negrette”, F. D. M., Vizcaíno-Carruyo, J., & Editorial Médica Colombiana, M. (2020) · Investigación Clínica · doi:10.22209/ic.v61n1a07
Fenster, B. E., Lee-Chiong, T. L., Gebhart, G. F., & Matthay, R. A. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00031-2
WITHDRAWN: Anticoagulation management strategies in heart transplantation
Rizk, J. G., & Mehra, M. R. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.01.004
RetractedUtilize the full potential of real world evidence
Bauersachs, R. M. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.10.008
Direct oral anticoagulants: A new chapter in anticoagulation therapy
Stepanović-Petrović, R. M., & Nastić, K. (2020) · Arhiv za farmaciju · doi:10.5937/arhfarm2005249s · Cited by 1
Updates on the use of direct oral anticoagulants for the management of chronic conditions
Gibson, C. M. (2020) · Pharmacy Today · doi:10.1016/j.ptdy.2020.11.019
Extended therapy and secondary prevention of venous thromboembolic complications
Petrikov, A. S., & Игоревич, П. И. (2020) · I P Pavlov Russian Medical Biological Herald · doi:10.23888/pavlovj2020284548-566
Instal·lacions tèrmiques d'un poliesportiu
de la Fuente, X. P. (2010) · RECERCAT (Consorci de Serveis Universitaris de Catalunya)
Es lohnt sich heute, länger zu antikoagulieren! Venöse Thromboembolie
Einecke, D. (2013) · CardioVasc · doi:10.1007/s15027-013-0068-0
Erküner, Ö. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210604oe
ANTITHROMBOTIC EFFECTS OF SULODEXIDE: A REVIEW ARTICLE
Frati-Munari, A. C., Lecuona-Huet, N. E., & Majluf‐Cruz, A. (2021) · INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH · doi:10.36106/ijsr/8746403
Direct Oral Anticoagulation in Cancer Patients
Bottino, R., Carbone, A., Liccardo, B., D’Andrea, A., Golino, P., Nigro, G., & Russo, V. (2021) · Springer eBooks · doi:10.1007/978-3-030-74462-5_10
Newer Oral Anticoagulants in Venous Thromboembolism
Modi, S., & Modi, R. (2021) · Journal of Indian College of Cardiology · doi:10.4103/jicc.jicc_73_20
Venöse Thromboembolie (VTE): Epidemiologie, Pathophysiologie und natürlicher Verlauf
Kasper, A., & Lindhoff‐Last, E. (2015) · Springer eBooks · doi:10.1007/978-3-642-54676-1_348-1
Venous Thromboembolic Disease: DVT and PE
Marik, P. E. (2014) · Springer eBooks · doi:10.1007/978-3-319-11020-2_27
Pussadhamma, B. (2014) · Srinagarind Medical Journal (SMJ) - ศรีนครินทร์เวชสาร · Cited by 3
Difficult Choice: When to Prolong Anticoagulation Therapy in Patients with Venous Thromboembolism?
Хрыщанович, В. Я., & Скобелева, Н. Я. (2021) · Кардиология в Беларуси · doi:10.34883/pi.2021.13.5.016
Quan, M. L. C., Glunz, P. W., & Luettgen, J. M. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc182.pub2
Rivaroxaban versus Dabigatran: A new era in venous thromboembolism treatment
Radak, Đ., Đukić, N., Nešković, M., Babić, S., Tanasković, S., Popov, P., & Gajin, P. (2016) · Medicinska istrazivanja · doi:10.5937/medist1601014r
“RE-MEDY[17] (Dabigatran) 2,866 55 61 DBRCNI DAB 150 mg BID Warfarin dose-adjusted (INR: 2.”
BackgroundInfluentialPathway for the Diagnosis and Management of Pulmonary Embolism
Herzog, E., Elbaz‐Greener, G., Planer, D., Koren, T., Amir, O., Shapiro, J. M., & Kalish, Y. (2021) · Springer eBooks · doi:10.1007/978-3-030-87090-4_1
Direct oral anticoagulant drugs in the treatment of pulmonary thromboembolism
Obradovic, S. D., Džudović, B., Šalinger-Martinović, S., Matijašević, J., & Kovacevic, T. (2022) · Galenika Medical Journal · doi:10.5937/galmed2201015o
Management of oral surgery patients undergoing hemostasis modifying therapy: a literature review
Lira, L. M. D., & Silva, L. C. F. (2022) · Pubsaúde · doi:10.31533/pubsaude9.a324
(2016) · VASA · doi:10.1024/0301-1526/a000487
5 pulmonary embolism (PE) Pulmonary Embolism
(2020) · Thieme eBooks · doi:10.1055/b-0040-177993
Tsagoudis, K., & Ostendorf, R. (2015) · Aktuelle Dermatologie · doi:10.1055/s-0034-1391974
Tosetto, A., Palareti, G., & Lillicrap, D. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14519
(2013) · British journal of surgery · doi:10.1002/bjs.9315
The Treatment of Venous Thromboembolism in Patients with Cancer
Prandoni, P. (2016) · Advances in experimental medicine and biology · doi:10.1007/13780_2016_27
Becattini, C., Giustozzi, M., & Agnelli, G. (2014) · Springer eBooks · doi:10.1007/978-3-642-37393-0_162-1
The Optimal Duration of Anticoagulation in Patients with Unprovoked Venous Thromboembolism
Prandoni, P. (2016) · Advances in experimental medicine and biology · doi:10.1007/13780_2016_29
Becattini, C., Giustozzi, M., & Agnelli, G. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_162
Hattori, T., & Shiono, M. (2014) · Journal of Nihon University Medical Association · doi:10.4264/numa.73.78
de Winter, M. A. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1132
4 Clinical applications of aspirin
Schrör, K. (2022) · De Gruyter eBooks · doi:10.1515/9783110746419-004
Protocolo de anticoagulación en la tromboembolia pulmonar
Durán, D., & Guerrero, R. M. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.11.017
Jing, R., Guo, S., & Li, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-2713998/v1
Management of Portal Vein Thrombosis Following Bariatric Surgery
Jester, G., Jacob, J. B., & Baidas, S. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-25828-2_50
Souza, D. H. I., de Almeida, N. A., Domingues, M. L. D. P., Baldoni, A. O., Baldoni, N. R., & Rios, D. R. A. (2023) · Medicina (Ribeirão Preto) · doi:10.11606/issn.2176-7262.rmrp.2023.196548
Galyfos, G. C., Chamzin, A., Charalampopoulos, G., Liasis, N., Sigala, F., & Filis, K. (2023) · Phlebology The Journal of Venous Disease · doi:10.1177/02683555231199004
“24,25 Besides triple-positive antiphospholipid syndrome, there is no of fi cial contraindication to use DOACs as a fi rst-line therapy in cases of thrombophilia.”
BackgroundErtürk, E., Ocak, K., Uyan, U., Çoner, A., Kocabaş, U., Kış, M., Başkurt, A. A., Oray, D., Sayın, B. Y., Mammadov, G., et al. (2023) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.2688
Oral anticoagulation therapy in the treatment of pulmonary thromboembolism
Omčikus, M., & Milivojević, I. (2023) · Galenika Medical Journal · doi:10.5937/galmed2305062o
Benz, A. P., & Hohnloser, S. H. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780192869227.003.0010
New Oral Anticoagulants – What’s New? A Systematic Review
dos Santos, J. G. D., Ferracioli, P. R. B., & Borges, W. R. (2023) · European Journal of Medical and Health Research · doi:10.59324/ejmhr.2023.1(3).01
Wille, H. (2023) · Springer eBooks · doi:10.1007/978-3-662-68371-2_9
Aspirine et prévention de la récidive de la maladie veineuse thromboembolique
Salah, R. B., Derbel, A., Chabchoub, I., Frikha, F., Marzouk, S., & Bahloul, Z. (2024) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2024.101761
Thrombosis, Hemostasis, and Cardiovascular Outcomes
Belur, A. D., Zheng, S., Raza, M., & Kalra, D. K. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_11 · Cited by 1
Tromboembolismo Pulmonar: Como Definir o Tempo de Anticoagulação?
Pereira, G. A., & Fagundes, M. C. (2024) · Revista Científica Hospital Santa Izabel · doi:10.35753/rchsi.v8i2.543
Aydın, E. G. G., Durceylan, E., Angın, Y. S., Basyazici, G., Özkara, E., Çeliksöz, A. H., Yılmaz, E., Ata, A. R., Akarsu, M., ÇINAROĞLU, A., et al. (2024) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.3173
Anticoagulants and Reversal Agents
Almohaish, S., & Brophy, G. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-62224-3_15
Alexandros, C., Dimitrios, L., Katerina, S., Georgios, C., & Galyfos, G. C. (2025) · International Journal of Vascular Surgery and Medicine · doi:10.17352/2455-5452.000047
The Effects of Statin Therapy on Mean Platelet Volume in Patients with Cardiovascular Diseases
Abdulrazzaq, A. A., Hani, R., & Saleh, A. R. (2025) · Stallion Journal for Multidisciplinary Associated Research Studies · doi:10.55544/sjmars.3.6.6
Lefebvre, M., Cachanado, M., Châtellier, G., & Emmerich, J. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.102928
“Four studies evaluated DOACs: THRIVE III [24], RE-SONATE [25], AMPLIFY-EXT [26], and EINSTEIN-EXT [27].”
Zeng, Z., Bea, S., Sreedhara, S. K., & Bykov, K. (2025) · American Journal of Epidemiology · doi:10.1093/aje/kwaf235
Ma, S., Fan, G., Xu, F., Zhang, X., Chen, Y., Tao, Y., Li, Y., Lyu, Y., Yang, P., Wang, D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26677073
Riess, H., Langer, F., Wormann, B. J., Onkologie, D. K. A. F. I., & Onkologie, D. G. F. H. U. M. O. A. F. I. (2019) · Informationszentrum Lebenswissenschaften (ZB MED) · doi:10.4126/frl01-006418182
Rivera-Caravaca, J. M., Harrison, S. L., Buckley, B. J. R., Fazio-Eynullayeva, E., Underhill, P., Marín, F., & Lip, G. Y. H. (2021) · Figshare · doi:10.6084/m9.figshare.16570909
Mattiozzi, M. (2022) · Electronic Theses and Dissertations Repository (University of Pisa)
Orsi, L. D. A. F. (2020) · Leiden Repository (Leiden University)
Tia, J. M., Casapao, J. C., Liangco, W. L., & Gaspar-Trinidad, E. Y. (2018) · Philippine Journal of Internal Medicine · doi:10.65564/pjim.19556baf0f
Waqas, M., Ahmed, M., Ibrahim, M., Nasir, M., Afridi, M. K., Fonarow, G. C., & Waqas, S. A. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001175
Nikolić, M., Miloradović, V., Savicic, T. D., Kovačević-Kuzmanović, A., Zec, N., Subotić, B., Džudović, B., & Obradovic, S. D. (2020) · Srce i krvni sudovi · doi:10.5937/siks2002050n
Tran, B. B., & Streiff, M. B. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag009
Bacha, Z. A. R. Y. A. B., Qazi, K., Khalid, A. A., Shah, Z. A., Khan, M. I., Sikandar, M., Sajjad, F., Saeed, S., Akbar, F., Siddique, K., et al. (2026) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000417
Mühlbauer, B. (2026) · Springer eBooks · doi:10.1007/978-3-662-72738-6_9
INDICACIONES Y TIPOS DE FILTROS DE VENA CAVA: REVISIÓN SISTEMÁTICA.
Muñoz, L. E., Jaramillo, I. A. H., Tolosa, A. V., Bazán, M. I. O., Sánchez, A. M. M., & Sobradiel, M. G. (2026) · Revista sanitaria de investigación. · doi:10.34896/rsi.2026.88.63.001
Kolluri, R., Froehlich, J. B., Abumoawad, A., Merli, G. J., & Topoulos, A. P. (2026) · Vascular Medicine · doi:10.1177/1358863x261426933
“21 Given that MTS represents a persistent anatomic risk factor, thrombotic MTS is often considered pathophysiologically analogous to unprovoked DVT, supporting prolonged or indefinite anticoagulation in selected patients with an acceptable bleeding risk.”
Choi, W.-I., Chiu, K., Jang, H.-J., Choi, J.-H., Lee, W., Kim, K.-H., Pai, P., Chang, W., Chen, C.-P., Clasen, M., et al. (2026) · Thrombosis Update · doi:10.1016/j.tru.2026.100240
Anticoagulants and Thrombolytics
Mones, J. V., Sharda, A. V., Lech, T. K., & Zwicker, J. I. (2026) · Springer eBooks · doi:10.1007/978-3-032-13858-3_47
Mantoo, M. R., Mantoo, D. S. R., Majeed, M. W., Kulkarni, A., Lone, H. P., Mansoor, M., & Roy, A. (2026) · Romanian Journal of Cardiology · doi:10.2478/rjc-2026-0014
Zuin, M., Ageno, W., Squizzato, A., Temporelli, P. L., Bilato, C., & Piazza, G. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04410-1
“The RE-SONATE trial supported such a finding with an NNT of 19 and an NNH of 20 with dabigatran, suggesting a more precarious balance between thrombotic and bleeding risks when using a full therapeutic dose [18].”
Steiner, D., Kitta, A., & Ay, C. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.05.030
A short history of anticoagulant therapy
Chan, N., Imiela, A. M., Carlin, S., & Hirsh, J. (2026) · Thrombosis Research · doi:10.1016/j.thromres.2026.109753
Guo, S.-J., Luo, H., Gao, R. L., Fan, R., Zhou, Y., & Jing, R. (2026) · Medicine · doi:10.1097/md.0000000000049507
“On the other hand, a clinically pertinent nonmajor bleeding event was demarcated by the presence of any of the ensuing conditions [14] : the formation of subcutaneous hematomas, instances of epistaxis necessitating medical intervention, instances of gross hematuria, and unexpected bleeding episodes…”
Couturaud, F., Jiménez, D., Sanchez, O., Turrini, M., Odeberg, J., Klok, F. A., Presles, É., Bourgain, C., Konstantinides, S., Huisman, M. V., et al. (2026) · Thrombosis and Haemostasis · doi:10.1055/a-2913-2857
Barbosa, A. D. M., Gervásio, F. M., & Rodrigues, W. F. (2026) · Artefactum · doi:10.23900/artefactum.v25i8.4116
Diaz, G. M., Sammak, S. E., Ossi, J., Costa, F., Mouawad, N. J., Jaber, W. A., Waheed, A., & Krittanawong, C. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103456
Chin, A. L., & O’Connell, J. B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-28432-8.00012-0
Krebs, J. R., Wakefield, T., & Jacobs, B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-28432-8.00048-x
Protocolo terapéutico de la tromboembolia pulmonar aguda y su prolongación
Gómez-Barreda, D. C., Guerrero, R. M., & Castro, D. J. (2026) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2026.10.026
Direkte orale Antikoagulantien: Welche Patienten eignen sich zur Behandlung mit diesen Substanzen?
Eichinger, S. (2015) · Wiener klinische Wochenschrift Education · doi:10.1007/s11812-015-0070-9
Metadata
- Authors
- Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Thrombosis Research Institute (GB)
- Krankenhaus Dresden-Friedrichstadt (DE)
- Sahlgrenska University Hospital (SE)
- Boehringer Ingelheim (Netherlands) (NL)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (United States) (US)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Brigham and Women's Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 709-718
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2112378432
- Cited by
- 983
- References
- 25
- Citations by year
- 2026: 22 · 2025: 26 · 2024: 42 · 2023: 32 · 2022: 38 · 2021: 65 · 2020: 62 · 2019: 67 · 2018: 90 · 2017: 71 · 2016: 103 · 2015: 124 · 2014: 141 · 2013: 97
- FWCI
- 135.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- dabigatran, warfarin, venous thromboembolism, long-term anticoagulation, recurrent venous thromboembolism, major bleeding, acute coronary syndrome, direct oral anticoagulants, non-inferiority, thromboprophylaxis, thrombolysis, anticoagulant reversal
- MeSH terms
- Dabigatran, Adolescent, Adult, Aged, Aged, 80 and over, Benzimidazoles, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Recurrence, Risk, Warfarin, beta-Alanine, International Normalized Ratio, Venous Thromboembolism, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.